Cilostazol
- Generic Name
- Cilostazol
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H27N5O2
- CAS Number
- 73963-72-1
- Unique Ingredient Identifier
- N7Z035406B
- Background
Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reduci...
- Indication
Indicated for the alleviation of symptoms of intermittent claudication (pain in the legs that occurs with walking and disappears with rest).
- Associated Conditions
- Intermittent Claudication
- Associated Therapies
- -
Cilostazol Stroke Prevention Study : A Placebo-controlled Double-blind Trial for Secondary Prevention of Cerebral Infarction.
- Conditions
- Interventions
- First Posted Date
- 2008-10-06
- Last Posted Date
- 2021-03-01
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 1095
- Registration Number
- NCT00766545
Effect of Cilostazol in the Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler
- First Posted Date
- 2008-08-26
- Last Posted Date
- 2011-09-05
- Lead Sponsor
- Inje University
- Target Recruit Count
- 203
- Registration Number
- NCT00741286
- Locations
- 🇰🇷
Wonju Christian Hospital, Wonju, Korea, Republic of
🇰🇷Sanbon Medical Center, Gunpo, Korea, Republic of
🇰🇷Ajou University Hospital, Suwon, Korea, Republic of
Bioequivalency Study of 100 mg Cilostazol Tablets Under Fasting Conditions
- Conditions
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 32
- Registration Number
- NCT00602173
- Locations
- 🇺🇸
CEDRA Clinical Research, LLC, Austin, Texas, United States
Bioequivalency Study of 50 mg Cilostazol Tablets Under Fasting Conditions
- Conditions
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 36
- Registration Number
- NCT00602407
- Locations
- 🇺🇸
CEDRA Clinical Research, LLC, Austin, Texas, United States
Triple Versus Dual Antiplatelet Therapy After ABT578-Eluting Stent
- First Posted Date
- 2008-01-10
- Last Posted Date
- 2010-03-18
- Lead Sponsor
- CardioVascular Research Foundation, Korea
- Target Recruit Count
- 486
- Registration Number
- NCT00589927
- Locations
- 🇰🇷
Seoul Veterans Hospital, Seoul, Korea, Republic of
🇰🇷Ulsan University Hospital, Ulsan, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness
- Conditions
- Interventions
- First Posted Date
- 2007-12-14
- Last Posted Date
- 2007-12-14
- Lead Sponsor
- Korea University Anam Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT00573950
- Locations
- 🇰🇷
Korea Univerisity Anam Hospital, Seoul, Korea, Republic of
Safety and Pharmacokinetics of Probucol and Cilostazol
- First Posted Date
- 2007-10-26
- Last Posted Date
- 2022-03-04
- Lead Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT00549978
- Locations
- 🇰🇷
Clinical Trial Center, Seoul National University Hospital, Seoul, Korea, Republic of
Overcome Biochemical Aspirin Resistance Through Cilostazol Combination
- First Posted Date
- 2007-03-13
- Last Posted Date
- 2010-01-18
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 244
- Registration Number
- NCT00446641
- Locations
- 🇰🇷
Jae-Kwan Cha, Busan, Korea, Republic of
🇰🇷Kangdong Sacred Heart Hospital, Hallym University, Seoul, Korea, Republic of
🇰🇷Eulji University Hospital, Daejon, Korea, Republic of
Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial Disease
- Conditions
- Interventions
- First Posted Date
- 2007-03-05
- Last Posted Date
- 2018-05-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 553
- Registration Number
- NCT00443287
- Locations
- 🇿🇦
Sanofi-Aventis Administrative Office, Midrand, South Africa
Effects of Cilostazol on VEGF and Oxidative Stress Biomarkers in Hemodialysis Patients With Peripheral Vascular Disease
- Conditions
- Interventions
- First Posted Date
- 2007-02-05
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- Tungs' Taichung Metroharbour Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT00431249
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.